- Home
- AXSM vs CRL Comparison
AXSM vs CRL Comparison
Compare AXSM & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXSM | CRL |
|---|---|---|
| Founded | 2012 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 7.5B |
| IPO Year | 2015 | 1999 |
Fundamental Metrics
Financial Performance| Metric | AXSM | CRL |
|---|---|---|
| Price | $169.68 | $167.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 12 |
| Target Price | ★ $210.65 | $200.09 |
| AVG Volume (30 Days) | 508.3K | ★ 751.1K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,857,601,000.00 |
| Revenue This Year | $58.18 | $0.99 |
| Revenue Next Year | $55.45 | $3.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $86.99 | $91.86 |
| 52 Week High | $191.50 | $228.88 |
Technical Indicators
Market Signals| Indicator | AXSM | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 49.75 |
| Support Level | $151.26 | $166.86 |
| Resistance Level | $191.13 | $182.76 |
| Average True Range (ATR) | 5.38 | 7.21 |
| MACD | 1.94 | 2.47 |
| Stochastic Oscillator | 76.52 | 58.54 |
Price Performance
Historical ComparisonAbout AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.